HIGD2A

Across TCGA pan-cancer cohorts, HIGD2A mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated HIGD2A data layer compared with 24 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher HIGD2A mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated HIGD2A expression acts as an unfavorable survival marker, although some lineages such as HNSC and COAD show a favorable association.

HNSC, COAD, and UCEC are the cancer types where HIGD2A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	III,IV	0.786	0.479	.001	48	view →
COAD	DFS	Median	All	1.000	0.923	.019	36	view →
UCEC	DFS	Median	All	0.932	1.000	.021	22	view →
CCRCC	OS	Median	III,IV	0.485	1.000	.036	12	view →
PDAC	OS	Median	II,III,IV	0.521	0.233	.040	4	view →
LUAD	DFS	Tertile	II,III,IV	0.591	0.870	.043	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

HIGD2A–HNSC (DFS)

Open the HNSC breakdown →